阿里健康(00241.HK)與拜耳達成合作 拓展慢病患者用藥管理服務
阿里健康(00241.HK)與德國藥企拜耳簽訂戰略合作協議,雙方將重點探索抗凝類藥物的患者管理業務,並將在藥品新零售、患者教育、在線醫藥服務等領域展深開度合作。
同時,依託於阿里健康領域生態佈局、自營鏈路及倉配體系,雙方並將在互聯網醫院項目、藥品新零售業務進行合作,探索線上處方流轉新模式,以期實現慢病患者的線上服務及全程管理,並計劃共建藥品業務品牌旗艦店,為患者提供更好的醫藥服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.